Clinical trial · Interventional
Dual-port Trans-subclavian Thyroid Endoscopic Surgery
Dual-port Trans-subclavian Thyroid Endoscopic Surgery - an Exploration of Cavity Construction in Situ Heralds a New Approach Choice
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, single-center, open-label, non-randomized controlled real-world study aimed at exploring a novel approach to cavity construction for thyroid endoscopic surgery. The study seeks to evaluate its effectiveness and safety while accumulating further evidence-based medical data. Three hundred patients with thyroid tumors were divided into an experimental group (150 cases receiving a new endoscopic thyroid surgery technique, namely, dual-port trans-subclavian thyroid endoscopic surgery) and a control group (150 cases undergoing traditional open thyroid surgery) according to their treatment intention. Laboratory and medical data from specified follow-up points are collected, and adverse events are recorded detailly. The primary efficacy endpoint is a comparison of surgical complications between the two treatment groups. Secondary endpoints include: (1) levels of IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ, renin, angiotensin II, and aldosterone preoperatively and on the second day postoperatively; (2) NRS scores on the first day postoperatively; (3) length of hospital stay, duration of surgery, total treatment cost, and postoperative drainage volume; and (4) assessment of wound satisfaction during a three-month follow-up visit. Safety assessments include adverse events, vital signs, and pathological examinations.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endoscopic Surgery | — | UNRESOLVED | — |
| Thyroid Neoplasms | Thyroid Gland Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Conventional open thyroidectomy (COT) | Procedure | — | UNRESOLVED |
| Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS). | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- DTS group
- description
- Patients undergo Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS)
- interventionNames
- Procedure: Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS).
- type
- ACTIVE_COMPARATOR
- label
- COT group
- description
- Patients undergo conventional open thyroidectomy (COT)
- interventionNames
- Procedure: Conventional open thyroidectomy (COT)
Primary outcomes (1)
- measure
- The incidence of postoperative complications
- timeFrame
- From the date of grouping to the first recorded progression of relapse or the date of death due to any cause, whichever came first, assessed up to 100 months.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Thyroid cancer or benign thyroid tumors * Patients with a demand for incisional cosmetic improvement Exclusion Criteria: * Patients with thyroid cancer larger than 2 cm * benign tumors larger than 5 cm * Patients with severe underlying diseases * Patients with chronic kidney disease, * Patients with autoimmune diseases * Patients with rheumatoid arthritis
References
Publications (0)
Data not yet available